查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1832039

2025 年至 2033 年生物样本库市场规模、份额、趋势及预测（按样本类型、生物样本库类型、应用、最终用户和地区划分）

Biobanking Market Size, Share, Trends and Forecast by Specimen Type, Biobank Type, Application, End-User, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 142 Pages | 商品交期: 2-3个工作天内

价格

2024年，全球生物样本库市场规模达643亿美元。展望未来， IMARC Group预测，到2033年，该市场规模将达到1,011亿美元，2025年至2033年的复合年增长率为5.2%。目前，北美占据市场主导地位，2024年的市占率将超过34%。基因组研究活动数量的增加、慢性病盛行率的上升以及对虚拟生物样本库的日益关注是推动市场发展的一些关键因素。

由于医学研究和个人化医疗对高品质生物样本的需求不断增长，全球生物样本库市场正在不断扩张。基因组学和蛋白​​质组学的进步推动了对保存完好的生物样本的需求，以支持药物研发、疾病诊断和生物标记开发。例如，梅奥诊所的个人化医疗中心于2024年8月启动了一项组学策略，整合基因组学、蛋白质组学、代谢组学和微生物组学，以探索基因与环境的相互作用。该计划致力于推进疾病的预测、诊断和管理，包括癌症和慢性病。该中心旨在利用多基因风险评分和先进的定序技术，提供个人化的医疗保健和创新的治疗方案。政府和私人部门对生物样本库基础设施的投资，以及对再生医学日益增长的关注，进一步推动了市场的发展。此外，自动化样本管理系统等先进储存技术的集成，提高了效率和可靠性，从而推动了市场的成长。

人们越来越意识到生物样本库在应对癌症和罕见疾病等全球健康挑战方面的重要性，这对市场产生了重大影响，尤其是在欧洲。采用数位平台进行资料管理和远端样本追踪，确保了更好的可访问性和透明度。此外，研究机构、製药公司和生物样本库之间的合作正在加速创新，强化了市场在支持临床研究和治疗进步方面的作用。例如，2024 年 4 月，欧洲创新与技术学院 (EIT) 旗下的 EIT Health Scandinavia 推出了 EIT Health 生物样本库和健康资料註册平台。该中心将研究人员、临床医生和行业专业人士与欧洲生物样本库和资料註册中心联繫起来。该平台由 BBMRI-ERIC 开发，简化了存取流程，提高了样本利用率，并促进了合作，从而推动医学研究和创新。

生物银行市场趋势：

生物样本库在基因组研究和个人化医疗中的作用不断扩大

目前，随着基因组研究活动的增多，对生物样本库的需求不断增长，这是支撑市场成长的关键因素之一。此外，由于生物样本库具有提高生物医学研究资料可重复性和意义的潜力，全球生物样本库数量不断增加，这也为市场前景提供了积极的信号。此外，糖尿病、高血压、癌症、心臟病和呼吸系统疾病等慢性疾病在世界各地人口中的发生率也在上升。世界卫生组织 (WHO) 报告称，慢性疾病每年导致 4,100 万人死亡，占全球死亡人数的 74%。再加上对生物样本库的需求不断增长，以开发能够有效识别病原体的诊断方法，共同推动了市场的成长。此外，再生医学、个人化医疗和癌症基因组研究等先进疗法的支出不断增加，为行业投资者提供了丰厚的成长机会。例如，英国生物样本库已收集了 50 万名参与者的基因资料，包括所有参与者的全基因组定序 (WGS)、47 万人的全外显子组定序 (WES) 以及 80 万个变异的基因分型，估计后将变异数扩展到 9,000 万。此外，临床实验室对用于开发基因检测方法的生物样本的需求不断增长，这也对市场产生了积极影响。此外，虚拟生物样本库日益受到关注，因为它可以最大限度地减少时间限制、产生高收入，并使研究人员能够顺利进行研究，这也促进了市场的成长。此外，主要参与者正在推出生物样本库软体解决方案，以帮助提高可见度并改善向客户提供的服务质量，从而加强市场成长。

数位生物银行解决方案的采用率不断提高

数位技术的应用正在改变全球生物银行市场，提高效率并确保更好的资料管理。虚拟生物银行因其消除地理和物流障碍的能力而越来越受欢迎，为研究人员提供了无缝存取生物样本和相关资料的途径。数位平台提高了透明度，实现了即时追踪并简化了操作，有助于提高样本的完整性。例如，2024 年 8 月，Verisense Health, Inc. 推出了 Verisense 数位生物银行，其中包含来自 100 多万人的健康资料，预计到 2024 年底将达到 200 万。它包含来自 570 项研究的资料，并使用人工智慧驱动的数据集编目器来管理和更新数据集。这有助于研究人员更有效地存取、验证和使用数位健康资料。此外，生物银行管理软体的进步使利害关係人能够优化储存条件、提高合规性并提高营运可扩展性，确保为研究和诊断提供高品质的生物样本。

慢性病研究中对生物样本的需求不断扩大

糖尿病、癌症和心血管疾病等慢性疾病的盛行率不断上升，推动了对生物样本的需求，以支持诊断和治疗的进步。生物样本库透过提供多样化的生物样本，在开发早期检测和治疗的创新解决方案方面发挥着至关重要的作用。例如，2024年11月，牛津奈米孔技术公司与英国生物样本库合作，开发了首个大规模表观遗传资料集，利用先进的DNA/RNA技术对5万个样本进行定序。该计画旨在揭示疾病机制、增强诊断能力并推动个人化治疗。透过提供近乎完整的表观基因组学见解，该计画支持医疗保健领域的突破，包括早期检测、个人化干预以及对疾病进展的深入了解。此外，由于慢性病占全球死亡人数的大多数，研究机构和製药公司正在利用生物样本库来加速临床试验并开发标靶疗法。总体而言，这一趋势凸显了生物样本库在应对全球医疗保健挑战和改善患者预后的重要性。

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 二手资料
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球生物样本库市场

  • 市场概况
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依样本类型

  • 血液製品
  • 实体组织
  • 细胞系
  • 核酸
  • 其他的

第七章：市场区隔：依生物样本库类型

  • 基于人群的生物样本库
  • 以疾病为导向的生物样本库

第 8 章：市场区隔：按应用

  • 疗法
  • 研究

第九章：市场区隔：依最终用户

  • 学术机构
  • 製药和生物技术公司

第十章：市场细分：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第 11 章：SWOT 分析

第 12 章：价值链分析

第 13 章：波特五力分析

第 14 章：价格分析

第 15 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Brooks Automation Inc.
    • Bay Biosciences LLC
    • Boca Biolistics
    • Ctibiotech
    • Cureline Inc.
    • Firalis
    • Greiner Bio-One International GmbH
    • Hamilton Company
    • Merck KGaA
    • ProteoGenex Inc.
    • Thermo Fisher Scientific Inc.
    • VWR Corporation (Avantor Inc.)
Product Code: SR112025A4967

The global biobanking market size was valued at USD 64.3 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 101.1 Billion by 2033, exhibiting a CAGR of 5.2% from 2025-2033. North America currently dominates the market, holding a market share of over 34% in 2024. The rising number of genomic research activities, increasing prevalence of chronic diseases, and rising focus on virtual biobank represent some of the key factors driving the market.

The global biobanking market is expanding due to increased demand for high-quality biological samples in medical research and personalized medicine. Advances in genomics and proteomics are driving the need for well-maintained biospecimens to support drug discovery, disease diagnosis, and biomarker development. For instance, in August 2024, Mayo Clinic's Center for Individualized Medicine launched an omics strategy, integrating genomics, proteomics, metabolomics, and microbiomics to explore gene-environment interactions. This initiative focuses on advancing disease prediction, diagnosis, and management, including cancer and chronic conditions. By utilizing polygenic risk scores and advanced sequencing, the center aims to deliver personalized healthcare and innovative treatment solutions. Government and private investments in biobanking infrastructure and the growing focus on regenerative medicine further boost the market. Additionally, the integration of advanced storage technologies, such as automated sample management systems, enhances efficiency and reliability, fueling market growth.

Rising awareness of the importance of biobanks in combating global health challenges, including cancer and rare diseases, is significantly influencing the market, especially in Europe. The adoption of digital platforms for data management and remote sample tracking ensures better accessibility and transparency. Moreover, collaborations between research institutions, pharmaceutical companies, and biobanks are accelerating innovations, reinforcing the market's role in supporting advancements in clinical research and therapeutics. For instance, in April 2024, EIT Health Scandinavia, part of the European Institute of Innovation and Technology (EIT), introduced the EIT Health Biobanks and Health Data Registries platform. This hub connects researchers, clinicians, and industry professionals with European biobanks and data registries. Developed with BBMRI-ERIC, it simplifies access, boosts sample utilisation, and fosters collaboration to drive medical research and innovation.

Biobanking Market Trends:

Expanding Role of Biobanking in Genomic Research and Personalized Medicine

At present, the rising demand for biobanking due to the increasing number of genomic research activities represents one of the key factors supporting the growth of the market. Besides this, the growing number of biobanks across the globe, due to its potential to enhance the reproductivity and meaning of data generated by biomedical research, is offering a positive market outlook. Additionally, there is a rise in the prevalence of chronic diseases, such as diabetes, hypertension, cancer, heart attack, and respiratory disorders, among the masses around the world. The World Health Organization (WHO) reports that chronic diseases account for 41 Million deaths annually, representing 74% of all global fatalities. This, coupled with the increasing demand for biobanking to develop diagnostics that can effectively identify pathogens, is propelling the growth of the market. Apart from this, the rising expenditure in advanced therapies, such as regenerative medicine, personalized medicine, and cancer genomic studies, is offering lucrative growth opportunities to industry investors. For instance, the UK Biobank has collected genetic data from 500,000 participants, including whole genome sequencing (WGS) for all, whole exome sequencing (WES) for 470,000, and genotyping of 800,000 variants, with imputation extending this to 90 Million variants. Moreover, the increasing demand for biospecimens from clinical labs to develop assays for genetic testing is positively influencing the market. In addition, the growing focus on virtual biobank that minimizes time constraints, generates high revenue, and allows researchers to conduct the research smoothly is contributing to the growth of the market. Furthermore, key players are introducing a biobank software solution that assists in gaining visibility and improving the quality of the service provided to customers, which is strengthening the market growth.

Increasing Adoption of Digital Biobanking Solutions

The adoption of digital technologies is transforming the global biobanking market, improving efficiency, and ensuring better data management. Virtual biobanks are gaining traction for their ability to eliminate geographical and logistical barriers, providing researchers seamless access to biospecimens and associated data. Digital platforms enhance transparency, enable real-time tracking, and streamline operations, contributing to better sample integrity. For instance, in August 2024, Verisense Health, Inc. launched the Verisense Digital Biobank, with health data from over one million people, expected to reach two million by the end of 2024. It includes data from 570 studies and uses an AI-powered Dataset Cataloger to manage and update datasets. This helps researchers access, validate, and use digital health data more efficiently. Additionally, advancements in biobank management software are enabling stakeholders to optimize storage conditions, improve compliance, and increase operational scalability, ensuring high-quality biospecimens for research and diagnostics.

Expanding Demand for Biospecimens in Chronic Disease Research

The rising prevalence of chronic diseases, such as diabetes, cancer, and cardiovascular conditions, is fueling demand for biospecimens to support diagnostics and therapeutic advancements. Biobanks play a vital role in developing innovative solutions for early detection and treatment by providing access to diverse biological samples. For instance, in November 2024, Oxford Nanopore Technologies partnered with UK Biobank to develop the first large-scale epigenetic dataset, sequencing 50,000 samples using advanced DNA/RNA technology. This initiative aims to uncover disease mechanisms, enhance diagnostics, and advance personalised treatments. By providing nearly complete epigenome insights, the project supports breakthroughs in healthcare, including early detection, tailored interventions, and improved understanding of disease progression. Moreover, with chronic diseases accounting for the majority of global fatalities, research institutions and pharmaceutical companies are leveraging biobanking to accelerate clinical trials and develop targeted therapies. Collectively, this trend underscores biobanking's importance in addressing global healthcare challenges and enhancing patient outcomes.

Biobanking Industry Segmentation:

Analysis by Specimen Type:

  • Blood Products
  • Solid Tissue
  • Cell Lines
  • Nucleic Acid
  • Others

According to the report, blood products are the leading specimen type in the global biobanking market, owing to their pivotal role in advancing medical research, diagnostics, and therapeutic innovations. Comprising plasma, serum, and whole blood, these samples are integral to studying biomarkers, genetic disorders, and disease mechanisms. Their widespread application in research on chronic conditions such as cancer, cardiovascular diseases, and diabetes highlights their significance. Blood products are also essential for infectious disease studies, aiding in vaccine development and diagnostics. The integration of advanced storage and preservation technologies ensures the integrity and reliability of these specimens, supporting their use in longitudinal and cross-sectional studies. Furthermore, the growing emphasis on precision medicine and genomics has amplified the demand for blood samples, as they enable the development of personalized therapeutic solutions. The expanding global biobanking infrastructure, coupled with collaborations among research institutions and pharmaceutical companies, enhances the accessibility and quality of blood specimens. This strong demand solidifies blood products' position as the dominant specimen type in the global biobanking market, driving innovation and contributing to improved healthcare outcomes.

Analysis by Biobank Type:

  • Population-based Biobanks
  • Disease-oriented Biobanks

According to the report, disease-oriented biobanks dominate the global biobanking market as they provide critical resources for advancing research and treatments focused on specific diseases. These biobanks collect, store, and manage biological samples, such as tissues, blood, and DNA, specifically related to conditions like cancer, cardiovascular diseases, and neurological disorders. Their targeted approach supports precision medicine initiatives by enabling the identification of disease biomarkers, understanding disease mechanisms, and developing tailored therapies. The increasing prevalence of chronic and rare diseases worldwide has amplified the demand for disease-oriented biobanks, driving investments from governments, research institutions, and pharmaceutical companies. Advanced data integration and sample management technologies further enhance their value, enabling seamless sharing of high-quality biospecimens and associated data. These biobanks also play a pivotal role in supporting clinical trials and accelerating the development of innovative diagnostics and treatments. With their focused contribution to global healthcare challenges, disease-oriented biobanks are the cornerstone of modern biobanking, ensuring meaningful progress in disease management and therapeutic advancements.

Analysis by Application:

  • Therapeutics
  • Research

According to the report, research is the leading therapeutics segment in the global biobanking market, driven by the increasing need for high-quality biospecimens to support advancements in medical science and therapeutic innovation. Biobanks are uniquely positioned as the main infrastructures sourcing samples and data for research on diseases and drug discovery and as nuanced repositories of biomarkers to help advance treatment outcomes. Nevertheless, the biobanks with a research orientation have emerged with the growth in precision medicine and genomics because of the maximum importance of developing biomolecules for treatment from the patient's genetic profile. Also, biobanks have the function of responding to the worldwide health problems by contributing to research on the chronic, infectious, and rare genetic diseases. Advancements in sample preservation and handling enhance the application of stored tissues a s useful tools of effective clinical trials and other applications. The relationship between biobanks, research institutions, and pharmaceutical companies enhance the ecosystem and overlays efficiency in discovery of treatments. This firm association with research activities places it as the largest therapeutics segment in the biobanking market, which is facilitating advancements in global healthcare.

Analysis by End-User:

  • Academic Institutions
  • Pharma and Biotech Companies

Pharma and biotech companies lead the market with around 58.3% of market share in 2024. Companies involved in pharma and biotech industries are highly motivated by the utilization of biospecimens in therapeutic products, trials, and precision medicine. These companies rely on biobanks to obtain high quality phenotype samples for biomarker identification, target validation as well as therapeutic validation. The inclusion of biobanking resources into the R&D value chains advances in the timeframe of the preclinical stage and increases productivity in drug development. Due to the trend towards the development of more and more chronic diseases and few occurrences of single diseases, there has been a growing need for various types of biological products, which can improve the methods of treatment for individuals and the technologies for tissue engineering and regeneration. Pharma and biotech firms also benefit from advanced biobank technologies, including automated storage systems and AI-driven data analytics, which enhance sample integrity and optimize utilization. Collaborations with biobanks provide these companies with access to ethically sourced specimens, ensuring compliance with regulatory standards and bolstering their research capabilities. By driving innovation and enabling groundbreaking therapies, pharma and biotech companies play a pivotal role in shaping the global biobanking market and advancing global healthcare solutions.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2024, North America accounted for the largest market share of over 34%. The North America region is driven by advanced healthcare infrastructure, significant investments in research and development, and a strong focus on precision medicine. The region benefits from robust biobank networks, supporting large-scale genomic and disease-specific research. Private sector initiatives in association with government funding are further improving the accessibility and quality of biospecimens, thereby forming strong stewardship. Moreover, North America is paying more attention to cutting-edge technologies adoption, including automated biobank management systems and AI-driven analytics. These technologies also improve sample preservation and data integration facilities that validates reliability for research applications. Increase in the incidences of chronic diseases such as cancer, and cardiovascular diseases put more emphasis on the procurement of good quality biospecimens for diagnostics and other therapeutic developments. This creates synergy among various institutions, research centers, and pharmaceutical industries with the result of promoting higher research outcomes of personalized medicine and regenerative options. North America, which continually exhibits a high level of commitment to legal requirements as well as ethics in biobanking, continues to lead in the growth of the worldwide business and its contributions to medical innovation.

Key Regional Takeaways:

United States Biobanking Market Analysis

The US accounted for 84.5% market share in North America. This can be attributed to the rising demand for personalized medicine, advancements in genomics, and increasing government investments in healthcare infrastructure. According to the U.S. Department of Health and Human Services, an estimated 129 Million Americans are affected by at least one major chronic disease, including heart disease, cancer, diabetes, obesity, and hypertension. This growing prevalence of chronic conditions has heightened the need for biobanks to support research in targeted therapies and precision medicine. Robust funding from institutions such as the National Institutes of Health (NIH) further accelerates biobank development, fostering advancements in genomics and biomedical research. Additionally, the integration of advanced technologies like artificial intelligence (AI) and machine learning enhances the analysis of complex datasets, significantly improving biobank capabilities. Collaboration among private biotech companies, academic institutions, and healthcare organizations strengthens the biobanking ecosystem. Regulatory frameworks, such as the Health Insurance Portability and Accountability Act (HIPAA), ensure secure management and sharing of biological data, instilling trust and encouraging participation. Together, these factors propel the growth of the U.S. biobanking market.

Asia Pacific Biobanking Market Analysis

The biobanking market in the Asia-Pacific (APAC) region is driven by advancements in healthcare infrastructure, increased government investment in research, and growing awareness of personalized medicine. According to the United Nations, China and India account for 18% of the world's population, providing a diverse genetic pool for biobank development. Also, according to the NIH, the 3 major NCDs in the Asia Pacific region are CVDs, cancer and diabetes due to the increasing loss of disability adjusted life years (DALYs). These nations, alongside Japan, play a significant role in advancing genomics research, particularly in cancer and genetic disorders. Expanding healthcare initiatives in countries like India and South Korea, coupled with supportive government policies, further stimulate market growth. International collaborations with global biopharmaceutical companies strengthen biobank capabilities, fostering innovation and research across the region. The combination of population diversity and research focus positions APAC as a key player in the global biobanking landscape.

Europe Biobanking Market Analysis

The European biobanking market is witnessing significant growth, driven by government funding, advancements in biotechnology, and the increasing emphasis on personalized medicine. According to the European Commission, over 35% of the EU population reported a chronic health condition in 2023, including cardiovascular diseases, diabetes, and cancer. This prevalence highlights the need for biobanks to support research and develop targeted therapies for these widespread conditions. Europe's strong healthcare infrastructure, coupled with its collaborative ecosystem of universities, research organizations, and private enterprises, provides a solid foundation for biobank development. Key initiatives, such as the EU's Horizon 2020 programme, have been instrumental in funding large-scale biobank projects focusing on genomics and disease-specific research. The adoption of advanced technologies and analytics further enhances the capabilities of European biobanks in managing and analyzing biological samples. Additionally, the region's stringent regulatory frameworks, including the General Data Protection Regulation (GDPR), ensure the ethical collection, storage, and use of biological data, fostering trust among stakeholders and encouraging public participation. These factors collectively position Europe as a global leader in biobanking, playing a crucial role in advancing medical research, supporting precision medicine, and addressing the growing healthcare challenges associated with chronic diseases.

Latin America Biobanking Market Analysis

The biobanking market in Latin America is driven by rising research investments and a growing focus on chronic disease management. According to the NIH, Brazil alone reported an estimated 928,000 deaths from chronic diseases, highlighting the need for enhanced medical research and biobank support. Governments in countries like Brazil and Mexico are strengthening healthcare infrastructure, creating opportunities for biobank development. Additionally, collaborations with international research institutions and private companies are improving biobank capabilities. While challenges like data management and regulatory frameworks persist, ongoing advancements in these areas are expected to drive further market growth in the region.

Middle East and Africa Biobanking Market Analysis

The Middle East and Africa biobanking market is gaining traction, driven by advancements in healthcare infrastructure and investments in cutting-edge technologies. In the UAE, the Al Jalila Foundation, part of the Mohammed Bin Rashid Al Maktoum Global Initiatives, invested USD 4.6 Million (AED 17 Million) to establish a state-of-the-art robotic biobank in 2022. Developed in collaboration with the Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU) and the Dubai Health Authority (DHA), the biobank will use advanced robotics and artificial intelligence to securely store over seven Million biological samples in cryogenic conditions below -80°C for genetic research. Such initiatives underscore the region's focus on leveraging technology to enhance research capabilities. Additionally, increasing government support and international collaborations further bolster the biobanking landscape in the region, paving the way for significant advancements in medical research and personalized medicine.

Competitive Landscape:

The global biobanking market is competitive, driven by advancements in technology, strategic collaborations, and the growing demand for high-quality biospecimens. Companies are focusing on developing innovative biobank management systems, automated storage solutions, and digital tools to enhance operational efficiency and meet research needs. Collaborative initiatives between biobanks, research organizations, and pharmaceutical firms are fostering innovation in genomic and personalized medicine. For instance, in August 2024, Owkin and Finnish Biobank Cooperative (FINBB) collaborated to advance medical research by applying AI to multimodal patient data. This partnership leverages 11 million biobank samples, biodata, and participant recruitment from Finland's public biobanks. By combining expertise and resources, the initiative aims to accelerate innovative treatments for diseases like inflammatory bowel disease through impactful public-private partnerships. The rise of virtual biobanking and digital platforms is intensifying competition by improving accessibility and scalability. Market players are also emphasizing regulatory compliance, expanding biobank networks, and investing in R&D to address evolving healthcare challenges, further shaping the competitive landscape.

The report provides a comprehensive analysis of the competitive landscape in the keyword market with detailed profiles of all major companies, including:

  • Brooks Automation Inc.
  • Bay Biosciences LLC
  • Boca Biolistics
  • Ctibiotech
  • Cureline Inc.
  • Firalis
  • Greiner Bio-One International GmbH
  • Hamilton Company
  • Merck KGaA
  • ProteoGenex Inc.
  • Thermo Fisher Scientific Inc.
  • VWR Corporation (Avantor Inc.)

Key Questions Answered in This Report

  • 1.What is Biobanking?
  • 2.How big is the biobanking market?
  • 3.What is the expected growth rate of the global biobanking market during 2025-2033?
  • 4.What are the key factors driving the global biobanking market?
  • 5.What is the leading segment of the global biobanking market based on the specimen type?
  • 6.What is the leading segment of the global biobanking market based on the biobank type?
  • 7.What is the leading segment of the global biobanking market based on the application?
  • 8.What is the leading segment of the global biobanking market based on the end-user?
  • 9.What are the key regions in the global biobanking market?
  • 10.Who are the key players/companies in the global biobanking market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Biobanking Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Specimen Type

  • 6.1 Blood Products
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Solid Tissue
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Cell Lines
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Nucleic Acid
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Biobank Type

  • 7.1 Population-based Biobanks
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Disease-oriented Biobanks
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Therapeutics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Research
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Academic Institutions
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Pharma and Biotech Companies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Brooks Automation Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
    • 15.3.2 Bay Biosciences LLC
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Boca Biolistics
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Ctibiotech
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
    • 15.3.5 Cureline Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
    • 15.3.6 Firalis
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
    • 15.3.7 Greiner Bio-One International GmbH
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
    • 15.3.8 Hamilton Company
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
    • 15.3.9 Merck KGaA
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 ProteoGenex Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
    • 15.3.11 Thermo Fisher Scientific Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 VWR Corporation (Avantor Inc.)
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio

List of Figures

  • Figure 1: Global: Biobanking Market: Major Drivers and Challenges
  • Figure 2: Global: Biobanking Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Biobanking Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Biobanking Market: Breakup by Specimen Type (in %), 2024
  • Figure 5: Global: Biobanking Market: Breakup by Biobank Type (in %), 2024
  • Figure 6: Global: Biobanking Market: Breakup by Application (in %), 2024
  • Figure 7: Global: Biobanking Market: Breakup by End User (in %), 2024
  • Figure 8: Global: Biobanking Market: Breakup by Region (in %), 2024
  • Figure 9: Global: Biobanking (Blood Products) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Biobanking (Blood Products) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Biobanking (Solid Tissue) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Biobanking (Solid Tissue) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Biobanking (Cell Lines) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Biobanking (Cell Lines) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Biobanking (Nucleic Acid) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Biobanking (Nucleic Acid) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Biobanking (Other Specimen Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Biobanking (Other Specimen Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Biobanking (Population-based Biobanks) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Biobanking (Population-based Biobanks) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Biobanking (Disease-oriented Biobanks) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Biobanking (Disease-oriented Biobanks) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Biobanking (Therapeutics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Biobanking (Therapeutics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Biobanking (Research) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Biobanking (Research) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Biobanking (Academic Institutions) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Biobanking (Academic Institutions) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Biobanking (Pharma and Biotech Companies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Biobanking (Pharma and Biotech Companies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: North America: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: North America: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: United States: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: United States: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Canada: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Canada: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Asia-Pacific: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Asia-Pacific: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: China: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: China: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Japan: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Japan: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: India: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: India: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: South Korea: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: South Korea: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Australia: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Australia: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Indonesia: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Indonesia: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Others: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Others: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Europe: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Europe: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Germany: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Germany: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: France: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: France: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: United Kingdom: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: United Kingdom: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Italy: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Italy: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Spain: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Spain: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Russia: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Russia: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Others: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Others: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Latin America: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Latin America: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Brazil: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Brazil: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Mexico: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Mexico: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Others: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Others: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Middle East and Africa: Biobanking Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Middle East and Africa: Biobanking Market: Breakup by Country (in %), 2024
  • Figure 79: Middle East and Africa: Biobanking Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: Global: Biobanking Industry: SWOT Analysis
  • Figure 81: Global: Biobanking Industry: Value Chain Analysis
  • Figure 82: Global: Biobanking Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Biobanking Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Biobanking Market Forecast: Breakup by Specimen Type (in Million USD), 2025-2033
  • Table 3: Global: Biobanking Market Forecast: Breakup by Biobank Type (in Million USD), 2025-2033
  • Table 4: Global: Biobanking Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 5: Global: Biobanking Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 6: Global: Biobanking Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Biobanking Market: Competitive Structure
  • Table 8: Global: Biobanking Market: Key Players